The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.

  title={The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.},
  author={Hiroyuki Takahashi and Masabumi Shibuya},
  journal={Clinical science},
  volume={109 3},
The VEGF (vascular endothelial growth factor) family and its receptors are essential regulators of angiogenesis and vascular permeability. Currently, the VEGF family consists of VEGF-A, PlGF (placenta growth factor), VEGF-B, VEGF-C, VEGF-D, VEGF-E and snake venom VEGF. VEGF-A has at least nine subtypes due to the alternative splicing of a single gene. Although the VEGF165 isoform plays a central role in vascular development, recent studies have demonstrated that each VEGF isoform plays distinct… 

Figures from this paper

Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.

This article aims to highlight the most recent data referring to the VEGF family and its receptors, as well as its implications in the angiogenesis process.

Targeting vascular endothelial growth factor in patients with squamous cell lung cancer.

Angiogenesis is regulated mainly by the binding of VEGF to VEGFR-2, which causes autophosphorylation in several tyrosine residues at the kinase domain and C-terminal tail, with activation of downstream pathways leading to endothelial cell proliferation, survival, migration, and permeability.

Molecular and functional diversity of vascular endothelial growth factors

The molecular and functional diversity of VEGF family proteins play multiple physiological roles, such as angiogenesis and lymphangiogenesis, while exogenous members (viral and snake venom VEGFs) display activities that are unique in physiology and function.

VEGF expression in pancreatic cancer and other malignancies: a review of the literature

VEGF-A is the most specific and prominent angiogenic factor among all family members and VEGFR-2 is themost important receptor in evaluating the angiogenesis in pancreatic cancer, so VEGF overexpression may be considered as a diagnostic marker and as a poor prognostic factor of the disease.

VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway

Knockdown studies of RhoA even with supplementation of VEGF-C or A has resulted in decreased endothelial cell proliferation and stress fiber formation, indicating that VEGf-C does promote angiogenesis via RHoA mediated pathway.


The work shows that PlGF exhibits a duality in modulation of angiogenesis and tumor growth in a VEGF-A-dependent manner, and uncovered the molecular mechanisms underlying the complex interplay between PlGF and VEGf-A.

The Role of the VEGF Family in Coronary Heart Disease

The aim of this review article is to present an overview of the available evidence supporting the VEGF family for treating CHD and give hints for further research.

Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells.

It is shown that matrix metalloproteinase-7 (MMP-7) degrades human sVEGFR-1, which increases VEGF bioavailability around the endothelial cells, and the presence of M MP-7 abrogates the inhibitory effect of sVEF-1 on VEGf-induced phosphorylation of VEGFs receptor-2 on HUVECs.

Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy

A structural viewpoint is used to summarise the current knowledge of VEGF-VEGFR activation and signal transduction and provides a rational basis towards reconciling V EGF and VEGFR structure and function in developing new therapeutics for a diverse range of ailments.

Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.

It is important to understand further the molecular mechanisms underlying not only V EGF-VEGFR signaling but also the VEGF-independent regulation of angiogenesis, and to learn how to improve anti-angiogenesis therapy.



Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

It is reported that embryonic angiogenesis in mice was not affected by deficiency of PlGF, andTransplantation of wild-type bone marrow rescued the impairedAngiogenesis and collateral growth in Pgf−/− mice, indicating that PlGF might have contributed to vessel growth in the adult by mobilizing bone-marrow–derived cells.

VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant

It is shown that an endogenous splice variant, VEGF165b, is expressed as protein in normal cells and tissues and is circulating in human plasma, and that it inhibits VEGf165-mediated angiogenesis in rabbit cornea and rat mesentery, suggesting that regulation of V EGF splicing may be a critical switch from an antiangiogenic to a proangiogenesis phenotype.

Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells

Two newly developed blocking monoclonal antibodies against Flt-1 and KDR indicate that DNA synthesis is preferentially mediated by KDR in VEGF-mediated effects in endothelial cells (ECs) and that cell migration appears to be more complicated.

Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.

Flt-1 has a dual function in angiogenesis, acting in a positive or negative manner in different biological conditions, as well as a positive regulator using its tyrosine kinase under pathological conditions when the Flt-1-specific ligand is abnormally highly expressed.

Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D

It is reported that the serine protease plasmin cleaved both propeptides from the V EGF homology domain of human VEGF-D and thereby generated a mature form exhibiting greatly enhanced binding and cross-linking of VEGFR-2 and V EGFR-3 in comparison to full-length material.

Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF165 and VEGF121 *

It is demonstrated that although VEGFR-2 and Npn-1 form a complex, this complex does not result in an increase in VEGF165 binding affinity, and data suggest a receptor-clustering role for NPN-1, as opposed to Npn -1 behaving as an affinity-converting subunit.

Ligand-induced Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Heterodimerization with VEGFR-2 in Primary Lymphatic Endothelial Cells Regulates Tyrosine Phosphorylation Sites*

The data suggest that the carboxyl-terminal tail of VEGFR-3 provides important regulatory tyrosine phosphorylation sites with potential signal transduction capacity and that these sites are differentially used in ligand-induced homo- and heterodimeric receptor complexes.

A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain*

Results indicate that VEGF-E is a novel type of endothelial growth factor, utilizing only one of the V EGF receptors, and carrying a potent mitogenic activity without affinity to heparin.

A Novel Snake Venom Vascular Endothelial Growth Factor (VEGF) Predominantly Induces Vascular Permeability through Preferential Signaling via VEGF Receptor-1*

The purification and characterization of a novel VEGF-like protein from Trimeresurus flavoviridis Habu snake venom is reported, suggesting that Habu snakes have acquired a highly purposive molecule for a toxin, which enhances the toxicity in envenomation without inducing effective angiogenesis and the following regeneration of damaged tissues.